Innoviva, Inc.INVAEarnings & Financial Report
Innoviva, Inc. is a healthcare company specializing in the development, commercialization, and royalty management of prescription therapeutics for respiratory diseases, infectious diseases, and critical care conditions. It partners with leading global pharmaceutical firms to deliver treatments for asthma, COPD and other chronic illnesses to patients across core markets including North America and Europe.
INVA Q4 FY2025 Key Financial Metrics
Revenue
$114.6M
Gross Profit
$75.7M
Operating Profit
$39.0M
Net Profit
$164.2M
Gross Margin
66.0%
Operating Margin
34.0%
Net Margin
143.2%
YoY Growth
24.8%
EPS
$2.19
Innoviva, Inc. Q4 FY2025 Financial Summary
Innoviva, Inc. reported revenue of $114.6M (up 24.8% YoY) for Q4 FY2025, with a net profit of $164.2M (up 707.4% YoY) (143.2% margin). Cost of goods sold was $38.9M, operating expenses totaled $36.7M.
Key Financial Metrics
| Total Revenue | $114.6M |
|---|---|
| Net Profit | $164.2M |
| Gross Margin | 66.0% |
| Operating Margin | 34.0% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Innoviva, Inc. Q4 FY2025 revenue of $114.6M breaks down across 4 segments, led by Royalty at $54.9M (47.9% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Royalty | $54.9M | 47.9% |
| Xacduro | $32.1M | 28.0% |
| Giapreza | $19.6M | 17.1% |
| Xerava | $7.3M | 6.4% |
Innoviva, Inc. Revenue by Segment — Quarterly Trend
Innoviva, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Royalty and Xacduro) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Royalty | $54.9M | $59.9M | $63.9M | $57.8M |
| Xacduro | $32.1M | $23.8M | $10.7M | $7.8M |
| Giapreza | $19.6M | $18.5M | $17.3M | $18.3M |
| Xerava | $7.3M | $4.9M | $7.1M | $4.2M |
Innoviva, Inc. Annual Revenue by Year
Innoviva, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $411.3M).
Innoviva, Inc. Quarterly Revenue & Net Profit History
Innoviva, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $114.6M | +24.8% | $164.2M | 143.2% |
| Q3 FY2025 | $107.8M | +20.4% | $89.9M | 83.4% |
| Q2 FY2025 | $100.3M | +0.4% | $63.7M | 63.5% |
| Q1 FY2025 | $88.6M | +14.4% | $-46.6M | -52.6% |
| Q4 FY2024 | $91.8M | +7.0% | $20.3M | 22.1% |
| Q3 FY2024 | $89.5M | +33.1% | $1.2M | 1.4% |
| Q2 FY2024 | $99.9M | +23.3% | $-34.7M | -34.7% |
| Q1 FY2024 | $77.5M | +1.5% | $36.5M | 47.1% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $77.5M | $99.9M | $89.5M | $91.8M | $88.6M | $100.3M | $107.8M | $114.6M |
| YoY Growth | 1.5% | 23.3% | 33.1% | 7.0% | 14.4% | 0.4% | 20.4% | 24.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.27B | $1.22B | $1.23B | $1.30B | $1.25B | $1.33B | $1.43B | $1.64B |
| Liabilities | $563.9M | $559.4M | $563.1M | $609.9M | $607.5M | $618.8M | $419.2M | $462.3M |
| Equity | $703.7M | $665.5M | $668.5M | $691.2M | $646.9M | $714.8M | $1.01B | $1.17B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $37.0M | $43.7M | $48.7M | $59.2M | $48.6M | $44.1M | $49.7M | $54.5M |